Where does OCRA's clinical trial data come from?

OCRA indexes clinical trials from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Trials are matched to diseases, investigators, and funded research tracked across the platform.

How do I find clinical trials for ovarian cancer?

Search by condition, treatment type, trial phase, or NCT identifier. Each trial page shows current status, eligibility criteria, study locations, and a direct link to the ClinicalTrials.gov source record.

How often is clinical trial data updated?

Trial data is refreshed through periodic ingestion from the ClinicalTrials.gov v2 API. Status changes, new enrollments, and newly registered trials are captured during each update cycle.

A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

NCT05375136CompletedOBSERVATIONAL

Summary

The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Lenvatinib in lenvatinib/pembrolizumab combination therapy in the post marketing setting: (1) Serious adverse events and serious adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in the approved product package insert of lenvatinib in lenvatinib/pembrolizumab combination therapy (3) Known adverse drug reactions (4) Non-serious adverse drug reactions (5) Other safety and efficacy related information.

Key Facts

Lead Sponsor

Eisai Korea Inc.

Enrollment

135

Start Date

2021-06-25

Completion Date

2023-11-07

Study Type

OBSERVATIONAL

Official Title

A Post Marketing Surveillance Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

Interventions

Non-interventional

Conditions

Endometrial NeoplasmsEndometriumCarcinomaRenal Cell Carcinoma

Eligibility

Age Range

18 Years+

Sex

ALL

Inclusion Criteria:

1. Greater than (\>) 18 years
2. Considered by the treating physician for lenvatinib/pembolizumab combination therapy for the approved indications in Korea, prior to study
3. Provided written consent for use of personal medical information for the study purpose
4. Meets the approved indication and none of the contraindications for lenvatinib/pembrolizumab combination therapy in Korea, as confirmed by the treating physician

Exclusion Criteria:

1\. Currently receiving lenvatinib and pembrolizumab as part of a clinical trial

Outcome Measures

Primary Outcomes

Number of Participants With Serious Adverse Events (SAEs)

A SAE is defined as any untoward medical occurrence: resulting in death; life threatening requiring hospitalization or prolongation of hospitalization; resulting in persistent or significant disability or incapacity; resulting in birth defect or congenital anomaly or medically important due to other reasons than above mentioned criteria.